The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
As the company has no listed peers, it is trying to extract fancy price for its IPO.
Based on its overall financial data, the issue appears fully priced.
Well-informed investors may park moderate funds for long term.
About Company
Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges.
The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).
QBLās key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipmentās & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.
It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipmentās and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipmentās and devices as per the technical collaboration and specifications provided by the partners or companies.
With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.
Issue Details / Capital History
The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share. The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes.
The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.
The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM groupās Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.
The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 ā Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.
Post-IPO, companyās current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr.
IPO Lead Managers & Registrar
Financial Performance
On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.
For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.
If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained.
For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.
All amounts in Indian Rupees crores
Period Ended
Revenue
Expense
PAT
Assets
2023
ā¹184.81
ā¹154.97
ā¹32.10
ā¹251.58
2024
ā¹206.45
ā¹175.85
ā¹34.44
ā¹339.25
2025
ā¹322.58
ā¹261.43
ā¹28.13
ā¹455.49
Dec 2025
ā¹236.50
ā¹186.96
ā¹38.69
ā¹561.34
Dividend Policy
The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects.
Comparison with Listed Peers - for Fiscal 2025
As per the offer document, the company has no listed peers to compare with.
Name of the Company
Face Value (ā¹)
EPS basic (ā¹)Ā
EPS Diluted (ā¹)
RONW (%)
P/E Ratio
NAV (ā¹)
Powerica Limited
5
15.26Ā
15.26
15.37 %Ā
24.45
99.76
Listed Peers
Cummins India Limited
2
72.15Ā
72.15
26.45%
64.13Ā
272.78
Kirloskar Oil Engines Limited
2
33.71
33.60
15.85%
43.24
212.60
NTPC Green Energy Limited
10
0.67
0.67
2.58%
129.40
21.88
Acme Solar Holdings Limited
2
4.55
4.53
5.59%
50.74Ā
74.54
Adani Green Energy Limited
10
8.37
8.37
11.90%Ā
101.53Ā
76.62
Disclaimer: Above table shows earnings and P/E ratio as of 2025-26
Merchant Banker's Track Record
The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.
Conclusion - Apply for medium to long term
QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.
Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.
He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.
Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.
FAQ Accordion
Q-Line Biotech IPO FAQs
1. What is Q-Line Biotech IPO?
ā
Q-Line Biotech IPO is SME IPO. The company is going to raise ā¹214 Crores via IPO. The issue is priced at ā¹326 to ā¹343 per equity share. The IPO is to be listed on NSE SME.
2. When Q-Line Biotech IPO will open for subscription?
ā
The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.
3. What is Q-Line Biotech IPO Investors Portion?
ā
The investorsā portion for QIB is 50%, NII is 15%, and Retail is 35%.
4. How to Apply the Q-Line Biotech IPO?
ā
You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.
5. What is Q-Line Biotech IPO Issue Size?
ā
Q-Line Biotech IPO issue size is ā¹214 crores.
6. What is Q-Line Biotech IPO Price Band?
ā
Q-Line Biotech IPO Price Band is ā¹326 to ā¹343.
7. What is Q-Line Biotech IPO Lot Size?
ā
The minimum bid is 800 Shares with ā¹2,74,400 amount.
8. What is the Q-Line Biotech IPO Allotment Date?
ā
Q-Line Biotech IPO allotment date is May 26,2026.
9. What is the Q-Line Biotech IPO Listing Date?
ā
Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.
Barbeque Nation IPO Date, Review, Price Band, Form & Market Lot Details
Barbeque Nation Hospitality aka Barbeque Nation is now ready to launch its IPO on 24 March 2021. Barbeque is one of India’s leading casual dining restaurant chains and is being managed by IIFL Securities, Axis Capital, Ambit Capital, and SBI Capital Markets. The promoters holding in the company is around 60.24% while CX Partners owns 33.79%. Barbeque Nation Hospitality has around 138 outlets across India and seven outlets in the UAE, Oman, and Malaysia. Check out Barbeque Nation IPO date, price band, and market lot details.
Interesting Facts:
The total debt of the company is around ā¹295 crore. The total number of shares will be around 3.34 crores after the IPO. In 2020 the PAT was (-ā¹33) crores with total revenues of ā¹851 crores. As we should ignore 2021 due to the pandemic and considering last 4 years the business is in loss but after the debt free EPS might come around ā¹50. The peer to peer Jubliant Food has PE of ā¹250. The coming years will be more interesting and profit making for a restaurant chain like Barbeque Nation.
How to apply the Barbeque Nation Hospitality IPO? You can apply Barbeque Nation IPO via ASBA available in your bank account. Just go to the online bank login and apply via your bank account by selecting Barbeque Nation IPO in the Invest section. The other option you can apply Barbeque Nation IPO via IPO forms download via NSE and BSE. Check out the Barbeque Nation forms – click NSE Forms & BSE Forms blank IPO forms download, fill, and submit in your bank or with your broker.
Link Intime India Private Limited C-101, 1stFloor, 247 Park, Lal Bahadur Shastri Marg Vikhroli (West) Mumbai, Maharashtra 400 083 Tel: +91 22 49186200 E-mail: bnhl.ipo@linkintime.co.in Investor grievance E-mail: bnhl.ipo@linkintime.co.in Contact Person: Shanti Gopalkrishnan Website: www.linkintime.co.in SEBI Registration No.: INR000004058
Note: Check Barbeque Nation Hospitality IPO allotment status on Linkintime website allotment URL. Click Here
Barbeque Nation IPO Lead Managers:
IIFL Securities Limited
Axis Capital Limited
Ambit Capital Private Limited
SBI Capital Markets Limited
Company Address:
Barbeque Nation Hospitality Ltd Head Office No 62, Site No, Survey, 13, 6th Cross Rd, NS Palya, Stage 2 BTM Layout, Bengaluru 560 076, Karnataka, India Tel: +91 080 61756070 Contact Person: Nagamani CY Company Secretary and Compliance Officer Tel: +91 80 4511 3000 Fax: +91 80 4511 3062 E-mail: compliance@barbequenation.com Website: www.barbeque-nation.com Corporate Identity Number: U55101KA2006PLC073031
Barbeque Nation IPO FAQs
When Barbeque Nation IPO will open for QIB, NII, and Retail?
The IPO is to open on 24 March 2021 for QIB, NII, and Retail Investors.
What is Barbeque Nation IPO Investors Portion?
The investors’ portion for QIB-75%, NII-15%, and Retail 10%.
How to Apply the Barbeque Nation IPO?
You can apply Barbeque Nation IPO via ASBA online via your bank account. You can apply ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.
How to Apply the Burger King IPO through Zerodha?
Log in to Console in Zerodha Website. Go to Portfolio and Click on IPO. You will see the IPO Name “Barbeque Nation”. Click on Bid Button. Enter your UPI ID, Quantity and Price. Submit IPO Application Form. Now go to your UPI App on Net Banking or BHIM App to Approve the mandate.
What is Barbeque Nation IPO Size?
Barbeque Nation IPO size is ā¹452.87 crores.
What is Barbeque Nation IPO Price Band?
Barbeque Nation IPO Price Band is ā¹499 – ā¹500.
What is Barbeque Nation IPO Minimum and Maximum Lot Size?
The minimum bid is 30 Shares with ā¹15000 amount while maximum bid is 390 shares with ā¹195000.
What is Barbeque Nation IPO Allotment Date?
Barbeque Nation IPO allotment date is 1 April 2021.
What is Barbeque Nation IPO Listing Date?
Barbeque Nation IPO listing date is 7 April 2021. The IPO to list on BSE and NSE.
Note: The IPO price band and dates will be added as it will be officially announced. The IPO grey market premium (Barbeque Nation IPO GMP) will be added on the grey market page as it will start)
Table of Contents
Jagat Joshi
Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.
